Cargando…

Comparison of Percutaneous Transluminal Angiography With or Without Catheter-Directed Thrombolysis for Chronic Femoropopliteal Occlusive Disease

BACKGROUND: Catheter-directed thrombolysis (CDT) is seldom used for chronic femoropopliteal occlusive disease. METHODS: Patients with chronic femoropopliteal occlusive disease enrolled between January, 2011 and April, 2017. Hospitalization expense, limb salvage rate and survival rate were calculated...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Mengfei, Guo, Jianjun, Gao, Yanxia, Ren, Jianzhuang, Bi, Yonghua, Han, Xinwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013675/
https://www.ncbi.nlm.nih.gov/pubmed/33783253
http://dx.doi.org/10.1177/10760296211005025
Descripción
Sumario:BACKGROUND: Catheter-directed thrombolysis (CDT) is seldom used for chronic femoropopliteal occlusive disease. METHODS: Patients with chronic femoropopliteal occlusive disease enrolled between January, 2011 and April, 2017. Hospitalization expense, limb salvage rate and survival rate were calculated. RESULTS: Twenty-nine patients were treated with CDT (CDT group) and 31 patients without CDT (Non-CDT group).The mean hospitalization expense (5.2 ± 0.5), balloon catheter (1.0 ± 0.2) and stents number (0.8 ± 0.2) in CDT group were significantly less compared to Non-CDT group (P < 0.05). The short-term and long-term effect scales showed similar in both groups. The incidences of perioperative complications (10.3% vs. 19.4%), primary patency and second patency rate, limb salvage rate (14.8% vs. 16.1%) and survival rate were also similar (P > 0.05). Six patients died in each group and only 2 disease related deaths were found in Non-CDT group. CONCLUSION: CDT is a safe and economic strategy for patients with chronic femoropopliteal occlusive disease, and should be served as blanket treatment for every patient without thrombolytic contradictions or a remedy for failure PTA to achieve a comparable clinical effect.